IRIS
MAFFEZZINI, MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.292
Totale 5.292
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 5.292
Totale 5.292
Salva come PNG Salva come JPEG
Città #
Genova 3.863
Rapallo 729
Genoa 403
Vado Ligure 247
Bordighera 50
Totale 5.292
Salva come PNG Salva come JPEG
Nome #
A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in men with prostate cancer. Efficacy monitored by karyometry. 146
Systemic absorption and pharmacokinetics of single-dose early intravesical mitomycin C after transurethral resection of non-muscle invasive bladder cancer. 134
Bladder cell culture on small intestinal submucosa as bioscaffold: Experimental study on engineered urothelial grafts 120
Adherence to Guidelines among Italian Urologists on Imaging Preoperative Staging of Low-Risk Prostate Cancer: Results from the MIRROR (Multicenter Italian Report on Radical Prostatectomy Outcomes and Research) Study. 119
A Multimodal Perioperative Plan for Radical Cystectomy and Urinary Intestinal Diversion: Effects, Limits and Complications of Early Artificial Nutrition 116
Are referral centers for non-muscle-invasive bladder cancer compliant to EAU guidelines? A report from the vesical antiblastic therapy Italian study. 114
Incidence and survival of rare urogenital cancers in Europe. 112
Evaluation of complications and results in a contemporary series of 300 consecutive radical retropubic prostatectomies with the anatomic approach at a single institution 111
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation 110
Pre-operative assessment of cancer in the elderly (PACE): A comprehensive assessment of underlying characteristics of elderly cancer patients prior to elective surgery 110
Large bladder diverticula: a comparison between laparoscopic excision and endoscopic fulguration 108
Age Is Predictive of Immediate Postoperative Urinary Continence after Radical Retropubic Prostatectomy 106
Developing a five-step training model for transperineal prostate biopsies in a naïve residents’ group: a prospective observational randomised study of two different techniques 106
Clinical outcome in testicular sex cord stromal tumors: testis sparing vs. radical orchiectomy and management of advanced disease 105
Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help - A SIOG surgical task force prospective study. 105
A Simple Mathematical Approach to Calculate Blood Loss in Radical Prostatectomy 104
Estimates of prostate cancer burden in Italy. 104
"What if…": decisional regret in patients who discontinued active surveillance 100
Postchemotherapy lymphadenectomy in patients with metastatic urothelial carcinoma: long-term efficacy and implications for trial design 98
A prognostic model including pre- and postsurgical variables to enhance risk stratification of primary mediastinal nonseminomatous germ cell tumors: the 27-year experience of a referral center. 98
Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinoma. 98
Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center. 98
Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder 96
Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. 95
Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapy. 94
Multimodal Perioperative Plan for Radical Cystectomy and Intestinal Urinary Diversion. I. Effect on Recovery of Intestinal Function and Occurrence of Complications 93
The clinical use of statistical permutation test methodology: a tool for identifying predictive variables of outcome. 93
For wider acceptance of radical cystectomy and extended pelvic lymphadenectomy 91
Active surveillance in young patients with prostate cancer: the unanswered question 91
Long-term efficacy and safety outcomes of modified (simplified) MVAC (methotrexate/vinblastine/doxorubicin/cisplatin) as frontline therapy for unresectable or metastatic urothelial cancer. 89
Fast-track surgery and technical nuances to reduce complications after radical cystectomy and intestinal urinary diversion with the modified Indiana pouch 88
The impact of prior TURP on radical prostatectomy surgical margins: a multicenter analysis. 86
Current perioperative management of radical cystectomy with intestinal urinary reconstruction for muscle-invasive bladder cancer and reduction of the incidence of postoperative ileus 86
Editorial comment on: long-term rates of undetectable psa with initial observation and delayed salvage radiotherapy after radical prostatectomy 85
Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. 83
TC Incidence Increasing: Spread the Word 82
Re: Vincent Cloutier, Umberto Capitanio, Laurent Zini, et al. Thirty-Day Mortality after Nephrectomy: Clinical Implications for Informed Consent. Eur Urol 2009;56:998-1005 81
Feeding Hungry Patients, Even Those Well Nourished 80
Integrated gene and miRNA expression analysis of prostate cancer associated fibroblasts supports a prominent role for interleukin-6 in fibroblast activation. 80
Re: Trends in hospital volume and operative mortality for high-risk surgery 80
High-Risk Prostate Cancer is Worth Further Risk Stratification 79
Systemic Absorption and Pharmacokinetics of Single-dose Intravesical Gemcitabine After Transurethral Resection of the Bladder in Non-muscle-invasive Bladder Cancer 78
Focal therapy in urology: kidney cancer 76
Short-Schedule Intravesical Gemcitabine with Ablative Intent in Recurrent Ta–T1, G1–G2, Low- or Intermediate-Risk, Transitional Cell Carcinoma of the Bladder 75
Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression. 75
Paraganglioma of the prostate in a young adult 74
Phase I-II Trial of Weekly Bicalutamide in Men with Elevated Prostate-Specific Antigen and Negative Prostate Biopsies 74
Prostatic metastases from testicular nonseminomatous germ cell cancer: two case reports and a review of the literature. 73
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. 72
Pharmacokinetics and toxicity of an early single intravesical instillation of gemcitabine after endoscopic resection of superficial bladder cancer 72
The magnitude of the problem and the burden of physicians and patient decisions 71
Systemic Absorption and Pharmacokinetics of Single-Dose, Post-TURB (Trans-Urethral Resection of Bladder), Intravesical Gemcitabine, in Non-Muscle Invasive Bladder Cancer. 71
Peri-operative management of ablative and reconstructive surgery for invasive bladder cancer in the elderly. 71
Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer 69
Osteopontin plasma levels does not detect prostate cancer in patientsreferred for diagnostic biopsy 59
Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability. 56
Bladder Cancer 55
Urinary Diversion and Morbidity After Radical Cystectomy for Bladder Cancer 51
The survival of patients with bone metastases from renal cell carcinoma 39
Prognostic Significance of Fluorescent In Situ Hybridisation in the Follow-up of Non-muscle-invasive Bladder Cancer 36
Response to editorial comment from Dr Todenhöfer and Dr Schwentner to recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading. 36
Totale 5.357
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.443
article - articoli 17.227
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 216
Totale 34.886
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.528 0 0 0 0 144 233 298 172 180 273 184 44
2020/2021471 42 53 36 48 24 39 15 54 24 71 30 35
2021/2022818 30 83 67 71 23 78 50 162 65 64 41 84
2022/2023856 74 47 3 96 102 146 0 99 142 3 138 6
2023/2024323 22 42 6 39 16 52 14 51 15 11 24 31
2024/2025250 5 84 23 58 80 0 0 0 0 0 0 0
Totale 5.357